Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SSGJ-705 monotherapy in advanced malignant tumors
NCT06390774Phase 1Recruiting
- Sponsor
- 3S Guojian Pharmaceutical
- Start
- May 2024
- Primary completion
- Dec 2026
- Modality
- Prophylactic Vaccines, Bispecific Antibodies, Therapeutic Vaccines
- Countries
- 1
01
Overview
Phase 1, open-label trial of SSGJ-705 in malignant solid tumor and non-small cell lung cancer (NSCLC) (4 arms), sponsored by 3S Guojian Pharmaceutical. Primary endpoints: Dose-Limiting Toxicities at 14 days, Adverse Events up to 1 year and 2 more. Started May 2024; status: recruiting.
02
Drugs
SSGJ-705
03
Conditions
malignant solid tumornon-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT06390774.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06390774.